Baker Brothers Life Sciences Files Intent to Sell $2.7M in Protara Therapeutics Shares
Summary
Baker Brothers Life Sciences, a former affiliate, filed a Form 144 indicating intent to sell 461,723 shares of Protara Therapeutics common stock, valued at approximately $2.7 million, continuing a pattern of stake reduction.
Key Events
-
Intent to Sell Shares
Baker Brothers Life Sciences, L.P., a former affiliate, filed a Form 144 indicating its intent to sell 461,723 shares of Protara Therapeutics common stock.
-
Significant Transaction Value
The proposed sale has an approximate market value of $2,701,080.00. This represents a notable reduction in stake from a significant institutional investor.
-
Continuation of Selling Trend
This filing is part of an ongoing pattern of sales from Baker Brothers Life Sciences and its affiliate 667, L.P., which have collectively sold over $10 million in shares in the past three months, and are proposing a combined 500,000 shares in this latest round of filings.
Analysis
This Form 144 indicates Baker Brothers Life Sciences, a former affiliate, intends to sell an additional 461,723 shares of Protara Therapeutics common stock, valued at approximately $2.7 million. This follows a series of similar filings from Baker Brothers and its affiliate 667, L.P. over the past two weeks, signaling a continued reduction in their stake. The combined proposed sale with 667, L.P. totals 500,000 shares. While the company recently announced positive interim results from its Phase 2 ADVANCED-2 trial on February 24, 2026, this ongoing institutional selling could create an overhang on the stock, suggesting a lack of long-term conviction from a significant former holder.
At the time of this filing, TARA was trading at $5.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $304.6M. The 52-week trading range was $2.77 to $7.82. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.